Bone marrow derived allogenic mesenchymal stem cells (ImmunityBio)

N/A

Report date: 2023/01/12 15:46:33

Base Information

Drug NameBone marrow derived allogenic mesenchymal stem cells (ImmunityBio)
Drug Alias NameBM-Allo.MSCBM-Allo-MSC
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Coronavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmunitybio Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmunitybio Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsCoronavirus Infections

Other Information

ATC CodeN/A
Related LinksN/A